New Antibody–Drug Conjugates for NSCLC in the Limelight: Expert Guidance on the Integration of TROP-2–Targeting Agents Into Clinical Practice

Gain an in-depth understanding of emerging TROP-2–targeting ADCs with downloadable slidesets and expert reviews and commentaries.

Share

Program Content

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.